natgillin/translations-raw huggingface dataset:
Patients must be monitored closely for infections including tuberculosis before, during and after treatment with Flixabi.
Prije, tijekom i nakon liječenja lijekom Flixabi bolesnike se mora pomno nadzirati kako bi se uočile infekcije, uključujući tuberkulozu.
Patients must be monitored closely for infections including tuberculosis before, during and after treatment with Inflectra.
Prije, tijekom i nakon liječenja lijekom Inflectra bolesnike se mora pomno nadzirati kako bi se uočile infekcije, uključujući tuberkulozu.
Patients must be monitored closely for infections including tuberculosis before, during and after treatment with Remicade.
Prije, tijekom i nakon liječenja lijekom Remicade bolesnike se mora pomno nadzirati kako bi se uočile infekcije, uključujući tuberkulozu.
Patients must be monitored closely for infections including tuberculosis before, during and after treatment with Remsima.
Prije, tijekom i nakon liječenja lijekom Remsima bolesnike se mora pomno nadzirati kako bi se uočile infekcije, uključujući tuberkulozu.
Patients must be monitored closely for infections including tuberculosis before, during and after treatment with Simponi.
Bolesnike se mora pažljivo pratiti zbog infekcija, uključujući i tuberkulozu, prije, tijekom i nakon liječenja lijekom Simponi.
Patients must be monitored closely for signs and symptoms of tuberculosis during and after treatment with Ilaris.
Bolesnike je potrebno pažljivo nadzirati zbog mogućih znakova i simptoma tuberkuloze tijekom i nakon liječenja Ilarisom.
Patients must be monitored during treatment to check their blood levels of platelets (components that help the blood to clot) and neutrophils (the white blood cells that fight infection).
Tijekom terapije treba nadzirati bolesnike kako bi se provjerile razine trombocita u krvi (komponenti koje pomažu pri grušanju krvi) i neutrofila (bijelih krvnih stanica koje se bore protiv infekcije).
Patients must be monitored for bronchial hyperresponsiveness to inhaled mannitol during their initiation dose assessment before commencing the therapeutic dose regimen of Bronchitol.
Pacijente se mora nadzirati zbog hiperreaktivnosti na inhalirani manitol tijekom procjenjivanja učinka početne doze, a prije nego se započne s uzimanjem terapijske doze Bronchitola.
Patients must be monitored for gastrointestinal signs and symptoms that may be indicative of immune- related colitis or gastrointestinal perforation.
Bolesnici se moraju nadzirati zbog znakova i simptoma probavnog sustava koji bi mogli ukazivati na imunološki uzrokovan kolitis ili gastrointestinalnu perforaciju.
Patients must be provided with the correct number of pens for their treatment course and educated to use the proper injection techniques.
Bolesnicima se mora dati točan broj brizgalica za njihovo liječenje, te ih se mora podučiti kako pravilno primjenjivati tehnike ubrizgavanja lijeka.
Patients must be vaccinated or revaccinated according to current national vaccination guidelines for vaccination use.
Bolesnike se mora cijepiti ili ponovno cijepiti u skladu s važećim nacionalnim smjernicama za cijepljenje.
Patients must be warned to store the blister safely, to never open the blister in advance, to keep them out of the reach of children and other household members, and not to take this medicine in front of children.
Bolesnike je potrebno upozoriti da pakiranja čuvaju na sigurnom, da blister nikada ne otvaraju unaprijed, da ga čuvaju izvan dohvata djece i drugih članova domaćinstva te da ne uzimaju lijek pred djecom.
Patients must have been stably suppressed (HIV-1 RNA < 50 copies/mL) on their baseline regimen for at least 6 months and had HIV-1 with no resistance mutations to emtricitabine or tenofovir alafenamide prior to study entry.
U bolesnika je HIV-1 morao biti stabilno suprimiran (HIV-1 RNK < 50 kopija/ml) početnim reţimom najmanje 6 mjeseci i biti bez mutacija povezanih s rezistencijom na emtricitabin ili tenofoviralafenamid prije ulaska u ispitivanje.
Patients must have confirmation of a breast cancer susceptibility gene (BRCA) mutation (either germline or tumour) before Lynparza treatment is initiated.
Prije početka liječenja lijekom Lynparza, kod bolesnica se mora potvrditi mutacija gena (u zametnim ili tumorskim stanicama) koji žene čini podložnima karcinomu dojke (BRCA).
Patients must have progressed within 6 months of their last chemotherapeutic regimen.
U bolesnika je bolest morala napredovati u roku od 6 mjeseci nakon posljednjeg kemoterapijskog režima.
Patients must not have experienced failure of a previous HIV therapy.
Pacijenti ne smiju imati neuspjeh u prethodnom liječenju infekcije virusom HIV-a.
Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Atripla prior to initiation of their first antiretroviral treatment regimen (see sections 4.4 and 5.1).
Prije započinjanja prvog režima antiretrovirusnog liječenja, pacijenti nisu smjeli doživjeti virološki neuspjeh na bilo koju raniju antiretrovirusnu terapiju i mora biti ustanovljeno da nisu nosili sojeve virusa s mutacijama koje pokazuju značajnu rezistenciju na bilo koju od tri komponente koje sadržava Atripla (vidjeti dio 4.4 i
Patients must not receive further Gazyvaro infusions if they experience:
Bolesnici ne smiju nastaviti primati infuzije lijeka Gazyvaro:
Patients must not take Zurampic if they suffer from tumour lysis syndrome (a complication due to the rapid breakdown of cancer cells during cancer treatment) or a rare hereditary disease called Lesch- Nyhan syndrome, both of which raise uric acid levels in the blood.
Bolesnici ne smiju uzimati Zurampic ako boluju od sindroma lize tumora (komplikacija uslijed brzog raspada stanica raka tijekom liječenja raka) ili rijetke nasljedne bolesti pod nazivom Lesch-Nyhanov sindrom, koje podižu razine mokraćne kiseline u krvi.
Patients must take oral folic acid or a multivitamin containing folic acid (350 – 1,000 µg) on a daily basis.
Bolesnici moraju svakodnevno peroralno uzimati folatnu kiselinu ili multivitaminski pripravak koji sadrži folatnu kiselinu (350 – 1000 mikrograma).
Patients must undergo appropriate thyroid blocking treatment prior to injection to minimise thyroid uptake of radioactive iodine, for example by oral administration of approximately 120 mg potassium iodide 1 to 4 hours prior to injection of DaTSCAN.
Pacijenti moraju primiti odgovarajuću terapiju za blokadu štitne žlijezde prije injekcije, kako bi se minimalizirao unos radioaktivnog joda u štitnjaču, na primjer peroralnim uzimanjem otprilike 120 mg kalijevog jodida 1 do 4 sata prije injekcije DaTSCAN-a.
Patients must wait at least 4 hours before treating another episode of BTP with PecFent.
Bolesnici moraju pričekati barem 4 sata prije nego što za drugu epizodu probijajuće boli primijene PecFent.
Patients naïve to immunoglobulin therapy
Bolesnici koji nisu nikada prije primali imunoglobuline
Patients need to be instructed that insulin glargine 100 units/ml products and Toujeo are not interchangeable and dose adjustments need to be made;
Bolesnike treba uputiti da pripravci inzulina glargina od 100 jedinica/ml i Toujeo nisu međusobno zamjenjivi i da je potrebno prilagoditi dozu;
Patients need to receive an initial higher dose (loading dose) on the first day.
Bolesnici moraju primiti prvu veliku dozu (dozu punjenja) prvoga dana.
patients not adequately controlled on a lower strength corticosteroid combination product
bolesnici u kojih bolest nije odgovarajuće kontrolirana primjenom kombiniranog lijeka koji sadrži kortikosteroid manje jačine
Patients not adequately controlled on metformin alone or in combination with other glucose-lowering medicinal products, including insulin, should receive a total daily dose of Ebymect equivalent to dapagliflozin 10 mg, plus the total daily dose of metformin, or the nearest therapeutically appropriate dose, already being taken.
Bolesnici u kojih glikemija nije dovoljno dobro regulirana metforminom samim ili u kombinaciji s drugim lijekovima za snižavanje razine glukoze, uključujući inuzlin, trebaju primati ukupnu dnevnu dozu lijeka Ebymect ekvivalentnu dozi dapagliflozina od 10 mg, plus ukupnu dnevnu dozu metformina ili najsličniju terapijski prikladnu dozu, koju bolesnik već uzima.
Patients not adequately controlled on metformin alone should receive a dose of this medicinal product equivalent to the total daily dose of saxagliptin 5 mg, dosed as 2.5 mg twice daily, plus the dose of metformin already being taken.
Bolesnici u kojih je glikemija neodgovarajuće kontrolirana samim metforminom moraju primati dozu ovog lijeka istovjetnu ukupnoj dnevnoj dozi od 5 mg saksagliptina, primijenjenoj u dozi od 2,5 mg dvaput na dan, uz dotadašnju dozu metformina.
Patients not currently treated with an erythropoiesis stimulating agent (ESA):
Bolesnici koji se trenutno ne liječe lijekovima za stimulaciju eritropoeze (LSE):
Patients not on dialysis require the lower starting dose: 3 tablets daily, in separated doses, with or immediately after meals of the day.
Bolesnicima koji nisu na dijalizi potrebna je niža početna doza: 3 tablete dnevno u podijeljenim dozama uz glavne dnevne obroke ili odmah nakon njih.
Patients not reported to have successful eschar removal
Bolesnici u kojih nije zabilježeno uspješno uklanjanje eshara
Patients not taking levodopa (early stage of Parkinson’s disease)
Bolesnici koji ne uzimaju levodopu (rana faza Parkinsonove bolesti)
Patients not using inhaled steroids
Bolesnici koji ne uzimaju inhalacijske steroide
Patients of age ≥75 years, of Asian race, with comorbidities (such as hypertension, and hepatic or renal impairment), or body weight below 60 kg appear to have reduced tolerability to lenvatinib (see section 4.8, Other special populations).
Čini se da bolesnici u dobi od ≥75 godina, azijatske rase, s komorbiditetima (kao što su hipertenzija i oštećenje funkcije jetre ili bubrega) ili tjelesne težine manje od 60 kg slabije podnose lenvatinib (vidjeti dio 4.8 Druge posebne populacije).
Patients of black African or Afro-Caribbean ancestry should therefore be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen whilst using Aerivio Spiromax.
Bolesnicima crnačkog afričkog ili afrokaripskog podrijetla stoga treba savjetovati da nastave s liječenjem, ali da potraže liječnički savjet ako simptomi astme ostanu nekontrolirani ili se pogoršaju dok primjenjuju Aerivio Spiromax.
Patients of black African or Afro-Caribbean ancestry should therefore be asked to continue treatment but to seek medical advice if asthma symptoms remain uncontrolled or worsen whilst using Aerivio Spiromax.
Bolesnicima crnačkog afričkog ili afrokaripskog podrijetla stoga treba savjetovati da nastave s liječenjem, ali da potraže liječnički savjet ako simptomi astme ostanu nekontrolirani ili se pogoršaju dok primjenjuju Airexar Spiromax.
Patients of non- Caucasian origin have not been included in these clinical studies.
U ova klinička ispitivanja nisu bili uključeni drugi bolesnici osim bolesnika bijele rase.
Patients of weight 20 to 55 kga
Bolesnici težine 20 do 55 kga
Patients older than 50 years of age (n=23) have been successfully treated with Busilvex without dose- adjustment.
Bolesnici stariji od 50 godina (n=23) uspješno su liječeni Busilvexom bez prilagođavanja doze.
Patients older than 50 years of age (n=23) have been successfully treated with busulfan without dose- adjustment.
Bolesnici stariji od 50 godina (n=23) uspješno su liječeni busulfanom bez prilagođavanja doze.
Patients on a controlled sodium diet must take this into consideration.
O tome treba voditi računa u bolesnika s ograničenjem unosa natrija.
Patients on an efavirenz-based regimen
Prethodni terapijski odgovor
Patients on antidepressants which affect noradrenergic transmission (e.g. tricyclic antidepressants and mianserin) (see section 4.5)
Bolesnici koji uzimaju antidepresive koji utječu na noradrenergički prijenos (npr. triciklički antidepresivi i mianserin) (vidjeti dio 4.5).
Patients on controlled sodium diet
Bolesnici na prehrani s kontroliranim unosom natrija
Patients on dabigatran etexilate who undergo surgery or invasive procedures are at increased risk for bleeding.
Bolesnici na dabigatraneteksilatu koji su podvrgnuti kirurškom zahvatu ili invazivnim postupcima imaju povećan rizik od krvarenja.
Patients on hydroxycarbamide should be made aware of the theoretical risks to the foetus.
Bolesnici koji primaju hidroksikarbamid moraju biti upoznati s teoretskim rizicima za fetus..
Patients on hydroxycarbamide wishing to conceive should stop treatment 3 to 6 months before pregnancy if possible.
Bolesnice koje uzimaju hidroksikarbamid, a žele zatrudnjeti, terapiju moraju prekinuti 3 do 6 mjeseci prije moguće trudnoće.
Patients on Kentera therapy should keep application sites covered with clothing when coming into contact with breast-feeding or pregnant women or breast-fed infants.
Bolesnici koji uzimaju terapiju Kentera moraju držati pokriveno mjesto primjene odjećom kada dolaze u dodir s dojiljama ili trudnim ženama ili dojenčadi.
Patients on Kentera therapy should keep application sites covered with clothing when coming into contact with breast-feeding or pregnant women or breast-fed infants.
Bolesnici koji uzimaju terapiju Kentera moraju odjećom držati pokriveno mjesto primjene kada dolaze u dodir s dojiljama, trudnim ženama ili dojenčadi.
Patients on mechanical ventilation
Bolesnici na mehaničkoj ventilaciji
Patients on oral antidiabetic agents receiving VELCADE treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their antidiabetics.
U bolesnika na terapiji oralnim antidijabeticima koji se liječe VELCADEom može biti potrebno pomno praćenje razine glukoze u krvi i prilagodba doze antidijabetika.
Patients on Revestive maintained their previous dose assignment throughout the extension phase, while placebo patients were randomised to active treatment, either 0.05 or 0.10 mg/kg/day.
Bolesnici koji su prethodno uzimali lijek Revestive nastavili su primati tu otprije utvrđenu dozu za čitavog trajanja faze produžetka, dok su bolesnici koji su prethodno primali placebo randomizirani na aktivno liječenje s 0,05 ili 0,10 mg/kg/dan.
Patients on stable dose of
su na stabilnoj dozi paroksetina i
Patients on stable dose of paroxetine who start
su na stabilnoj dozi paroksetina i
Patients on temsirolimus who develop thrombocytopaenia may be at increased risk of bleeding events, including epistaxis (see section 4.8).
Bolesnici koji primaju temsirolimus i razviju trombocitopeniju mogu biti pod povišenim rizikom od krvarenja, uključujući epistaksu (vidjeti dio 4.8).
Patients on temsirolimus with baseline neutropaenia may be at risk of developing febrile neutropaenia.
Bolesnici s početnom neutropenijom koji primaju temsirolimus mogu biti pod povećanim rizikom od razvoja febrilne neutropenije.
Patients on the comparator arm received cisplatin (P) 100 mg/m² as a 30-minute to three-hour intravenous infusion on day 1 followed by the continuous intravenous infusion of 5-fluorouracil (F) 1000 mg/m²/day from day 1 to day 5.
Bolesnici u usporednoj skupini primali su cisplatin (P) 100 mg/m2 kao 30-minutnu do trosatnu intravensku infuziju na dan 1, nakon čega je slijedila kontinuirana intravenska infuzija 5-fluorouracila (F) 1000 mg/m2 dnevno od dana 1 do dana 5.
Patients on the docetaxel arm received docetaxel (T) 75 mg/m2 followed by cisplatin (P) 75 mg/m2 followed by
Bolesnici u docetaksel skupini primali su docetaksel (T) 75 mg/m2 nakon čega je slijedio cisplatin (P)
Patients on the docetaxel arm received docetaxel (T) 75 mg/m2 followed by cisplatin (P) 75 mg/m2 followed by fluorouracil (F) 750 mg/m2 per day as a continuous infusion for 5 days.
Bolesnici u docetaksel skupini primali su docetaksel (T) 75 mg/m2 nakon čega je slijedio cisplatin (P) 75 mg/m2 te 5-fluorouracil (F) 750 mg/m2 na dan u obliku kontinuirane infuzije tijekom 5 dana.
Patients on the docetaxel arm received docetaxel (T) 75 mg/m² by intravenous infusion on day 1 followed by cisplatin (P)
Bolesnici u docetaksel skupini primali su docetaksel (T)
Patients on the docetaxel arm received docetaxel (T) 75 mg/m² by intravenous infusion on day 1 followed by cisplatin (P)
Bolesnici u docetaksel skupini primali su docetaksel (T) 75 mg/m2 intravenskom. infuzijom na dan 1 nakon čega je slijedio cisplatin (P)
Patients on the docetaxel arm received docetaxel (T) 75 mg/m² by intravenous infusion on day 1 followed by cisplatin (P) 100 mg/m² administered as a 30-minute to three-hour intravenous infusion, followed by the continuous intravenous infusion of 5-fluorouracil (F) 1,000 mg/m²/day from day 1 to day 4.
Bolesnici u docetaksel skupini primali su docetaksel (T) 75 mg/m2 intravenskom. infuzijom na dan 1 nakon čega je slijedio cisplatin (P) 100 mg/m2 primijenjen kao 30-minutna do 3-satna intravenska infuzija praćena kontinuiranom intravenskom infuzijom 5-fluorouracila (F) 1000 mg/ m2 dnevno od dana 1 do dana 4.
Patients on the TAC arm received antibiotic prophylaxis with ciprofloxacin 500 mg orally twice daily for 10 days starting on day 5 of each cycle, or equivalent.
Bolesnici u TAC skupini primali su antibiotsku profilaksu s ciprofloksacinom 500 mg peroralno dvaput na dan u trajanju od 10 dana, počevši od petog dana svakog ciklusa, ili ekvivalentni antibiotik.
Patients on the TPF arm received antibiotic prophylaxis with ciprofloxacin 500 mg orally twice daily for 10 days starting on day 5 of each cycle, or equivalent.
Bolesnici u TPF skupini primali su antibiotsku profilaksu ciprofloksacinom 500 mg oralno dva puta na dan tijekom 10 dana koju su počeli uzimati na peti dan svakog ciklusa, ili ekvivalentnim antibiotikom.
Patients on the TPF arm received antibiotic prophylaxis with ciprofloxacin 500 mg orally twice daily for 10 days starting on day 5 of each cycle, or equivalent.
Bolesnici u TPFskupini primali su antibiotsku profilaksu ciprofloksacinom 500 mg oralno dva puta dnevno tijekom 10 dana koju su počeli uzimati na peti dan svakog ciklusa, ili ekvivalentnim antibiotikom.
Patients on the TPF arm received antibiotic prophylaxis with ciprofloxacin 500 mg orally twice daily for 10 days starting on day 5 of each cycle, or equivalent.
kupini primali su antibiotsku profilaksu ciprofloksacinom 500 mg oralno dva puta dnevno tijekom 10 dana koju su počeli uzimati na peti dan svakog ciklusa, ili ekvivalentnim antibiotikom.
Patients on treatment with potent inhibitors of OATP1B1 (e.g. cyclosporine)
Bolesnici koji se liječe potentnim inhibitorima OATP1B1 (npr. ciklosporin)
Patients or carers may be able to give NovoSeven themselves after suitable training.
Bolesnici ili njegovatelji mogu sami davati NovoSeven nakon što su prikladno podučeni.
Patients or their caregivers should be instructed on the appropriate procedure for disposal of the vials, syringes and needles in accordance with local requirements.
Bolesnici ili njihovi njegovatelji moraju dobiti upute o primjerenom postupku odlaganja bočica, štrcaljki i igala u skladu s lokalnim propisima.
Patients or their carers can give injections of ReFacto AF, provided that they have been trained appropriately.
Bolesnici ili njihovi skrbnici mogu davati injekcije s lijekom ReFacto AF, uz uvjet da su dobili prikladnu obuku.
Patients or their carers can inject the medicine once they have been properly trained by a healthcare professional.
Bolesnici ili njihovi njegovatelji mogu sami injicirati lijek nakon što su prošli odgovarajuću obuku od strane zdravstvenih djelatnika.
Patients or their carers may be able to administer NovoEight themselves at home once they have been trained appropriately.
Bolesnici ili njihovi pružatelji skrbi mogu i sami primijeniti NovoEight u svom domu nakon što su završili odgovarajuću obuku.
Patients or their carers may be able to administer Nuwiq themselves at home once they have been trained appropriately.
Bolesnici ili njihovi njegovatelji moraju biti u stanju primijeniti Nuwiq sami kod kuće nakon što prođu odgovarajuću obuku.
Patients or their carers may be able to administer the treatment themselves at home if their treating physician feels this is appropriate and once they have been trained appropriately.
Bolesnici ili njihovi njegovatelji mogu sami primjenjivati terapiju kod kuće ako ordinirajući liječnik smatra da je to primjereno, te po završetku odgovarajuće obuke.
Patients over 60 years of age may be at greater risk for mild (>3xULN) to severe (>8xULN) elevation of ALT.
Bolesnici stariji od 60 godina mogu biti pod većim rizikom od blagog (>3 x GGN) do teškog (>8 x GGN) povećanja ALT-a.
Patients participating in all Phase 2 and Phase 3 psoriasis studies were eligible to enroll into an open- label extension trial, where Humira was given for at least an additional 108 weeks.
Bolesnici koji su sudjelovali u svim ispitivanjima faze II i III kod psorijaze ispunili su kriterije za uključivanje u otvoreni produžetak ispitivanja, gdje se Humira primjenjivala još najmanje dodatnih 108 tjedana.
Patients participating in Studies HS-I and HS-II were eligible to enroll into an open-label extension study in which Humira 40mg was administered every week.
Bolesnici koji su sudjelovali u ispitivanjima HS-I i HS-II mogli su sudjelovati u otvorenom produžetku ispitivanja u kojem se Humira primjenjivala svaki tjedan u dozi od 40 mg.
Patients participating in these studies could subsequently receive multiple courses of Cayston in an open-label follow-on study (CP-AI-006).
Bolesnici koji su sudjelovali u tim ispitivanjima naknadno su mogli primiti više kura Caystona u otvorenom ispitivanju nastavka liječenja (CP-AI-006).
Patients presented with a constellation of signs and symptoms, primarily respiratory, cardiovascular, edematous and/or cutaneous in nature (see section 4.4).
U bolesnika se javio niz znakova i simptoma, prvenstveno respiratornih, kardiovaskularnih, edematoznih i/ili kožnih (vidjeti dio 4.4).
Patients presenting end stage renal disease (creatinine clearance (CLCR< 15 mL/min/1.73 m2), by their condition and the limited amount of data available should be treated with caution and monitored carefully during treatment (see sections 4.4 and 5.2).
Bolesnike koji su u terminalnoj fazi bubrežne bolesti (klirens kreatinina (CLCR< 15 mL/min/1,73 m2), prema njihovom stanju i ograničenoj dostupnosti podataka treba liječiti uz oprez i pomno ih nadzirati tijekom liječenja (vidjeti dijelove 4.4 i 5.2).
Patients presenting with pruritus and/or persistent diarrhoea should be investigated for a potential overdose by a serum and/or urine bile acid assay (see section 4.9).
U bolesnika sa svrbežom i/ili dugotrajnim proljevom treba provjeriti potencijalno predoziranje pomoću testa za žučne kiseline u serumu i/ili urinu (vidjeti dio 4.9.).
Patients presenting with serious lung events that do not respond to conventional antimicrobial therapy should be assessed for drug-induced pneumonitis.
U pacijenata u kojih se jave ozbiljni plućni događaji koji ne odgovaraju na uobičajenu antimikrobnu terapiju takve događaje treba procijeniti kao pneumonitis uzrokovan lijekom.
Patients previously exposed to natalizumab should normally wait a minimum of 12 weeks prior to initiating therapy with Entyvio, unless otherwise indicated by the patient’s clinical condition.
Bolesnici prethodno izloženi natalizumabu trebali bi pričekati najmanje 12 tjedana prije početka liječenja lijekom Entyvio, osim ako bolesnikovo kliničko stanje ne iziskuje drugačije.
Patients previously Insulin naive or on basal isnulin
Bolesnici koji prethodno nisu bili liječeni inzulinom ili koji su prethodno bili liječeni bazalnim inzulinom
Patients previously on other phosphate binders who are switched to Fexeric should start taking 3 to 6 g (3 to 6 tablets) per day.
Bolesnici koji su prethodno uzimali druge vezače fosfata, a prebačeni su na Fexeric trebaju početi uzimati 3 do 6 g dnevno (3 do 6 tableta).
Patients previously taking only aliskiren or hydrochlorothiazide may need to take the two substances as separate tablets and adjust the doses before switching to Rasilez HCT.
Bolesnici koji su prethodno uzimali samo aliskiren ili hidroklorotiazid možda će morati uzeti dvije tvari kao zasebne tablete te prilagoditi doze prije prelaska na Rasilez HCT.